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endothelial dysfunction; and increased late systolic pressure augmentation from arterial wave reflections. Skeletal muscle abnormalities in HFpEF include greater adipose deposition; a shift from type I slow-twitch oxidative fibres to more easily fatigable type II fibres; and a reduction in capillary blood flow and oxygen delivery to exercising muscle. 2 Multiple mechanisms may co-exist to produce symptoms, and the extent to which each mechanism is contributory varies widely between patients.
The vasodilator trials of the 1980s were the first to demonstrate that organic nitrates improve exercise capacity, reduce symptoms, and prolong life in patients with mild-to-moderate HFrEF. 3 Organic nitrates reduce ventricular preload by increasing peripheral venous capacitance, which decreases LV filling pressures and wall stress. At higher doses, organic nitrates induce vasodilatation of the pulmonary and systemic resistance arterioles, as well as the coronary arteries. Some studies have shown that acute administration of organic nitrates also delay the return of peripheral artery reflected waves, which could otherwise increase pulsatile systolic afterload on the left ventricle and impair diastolic relaxation. 4 Despite the success of organic nitrates in HFrEF, and their frequent empiric use in HFpEF, there was an unmet need to systematically study this class of drugs in a randomized controlled trial in HFpEF patients. Thus, the Nitrate's Effect on Activity Tolerance in HFpEF (NEAT-HFpEF) was designed and conducted in HFpEF patients. 
NEAT-HFpEF trial results
The NEAT-HFpEF trial is the largest randomized controlled trial to date of organic nitrate therapy in patients with HFpEF. 5 Investigators used patient-worn accelerometers to measure the impact of isosorbide mononitrate (ISMN), an organic nitrate, on daily physical activity in 110 patients with HFpEF at a maximally tolerated dose (30-120 mg once daily) in a crossover trial design. HFpEF patients were treated with ISMN and placebo, each for 6 weeks, with the treatment order randomized; thus, patients served as their own controls. Patients treated with ISMN compared to placebo showed a significant decrease in hours of activity per day (-0.30 hours; 95% confidence interval -0.55 to -0.05, P = 0.02) and dose-dependent decrease in daily activity levels with no improvement in exercise capacity (6-minute walk test), quality of life, or natriuretic peptide levels.
5
Why did organic nitrate therapy worsen symptoms in heart failure with preserved ejection fraction?
The most common side effect of organic nitrates is headache. Indeed, in the NEAT-HFpEF trial, 16 participants discontinued ISMN, and 9 of these participants (56%) discontinued the study drug because of headaches (the most frequent cause of study drug discontinuation). 5 In addition, nitrate-induced systemic hypotension is also particularly limiting in patients with HFpEF. A steeper end-systolic pressure volume relationship means stroke volume increases less and systolic LV pressure decreases more in response to a decrease in preload or afterload. 6 Furthermore, deficient LV systolic reserve contributes to exercise limitation, and therefore excessive decrease in preload from nitrates can trigger baroreceptor-mediated tachycardia and offset any beneficial effects on myocardial performance. Finally, patients with HFpEF are frequently elderly and may have autonomic dysfunction, chronotropic incompetence, and altered baroreflex sensitivity, all of which may exaggerate hypotension with changes in load. 5 For these reasons, the decreases in physical activity observed in the NEAT-HFpEF trial have been ascribed to the deleterious cerebral and systemic vascular effects of organic nitrates in HFpEF, though these effects were not examined in the NEAT-HFpEF trial.
Inorganic nitrates: a superior alternative to organic nitrates in heart failure with preserved ejection fraction?
Both organic and inorganic nitrates impact the cardiovascular system by increasing NO bioavailability to activate cyclic GMP (cGMP)-mediated transduction pathways producing smooth muscle relaxation and vasodilatation. However, differences in physical chemistry underlie the potential pharmacokinetic and pharmacodynamic advantages of inorganic nitrates (i.e. nitrites) in HFpEF.
Inorganic nitrates (NO 3 ) and nitrites (NO 2 ) are naturally occurring, water-soluble anions, often bound to a metal cation such as sodium or potassium. They can be found in high concentrations in certain green leafy vegetables (e.g. beetroot, arugula), and they are also generated endogenously through the oxidative recycling of NO and subsequent excretion by the salivary glands (enterosalivary circulation pathway). Inorganic NO 3 is reduced to NO 2 by bacteria within the oral cavity and absorbed in the upper gastrointestinal tract with nearly 100% bioavailability.
. Alternatively, inorganic NO 2 can be directly administered intravenously or by inhalation. Ultimately, the reduction of inorganic NO 2 to NO via the nitrate-nitrite-NO pathway is triggered by: (i) a non-enzymatic mechanism in the acidic stomach; (ii) a hypoxia and acidosis-dependent mechanism, which selectively vasodilates the smaller resistance arterioles during exercise; and (iii) a paradoxical normoxia-dependent mechanism, which acts on the larger muscular conduit arteries, 7 and explains the impact on arterial wave reflections returning to the aorta. Importantly, inorganic NO 3 and NO 2 (nitrites) have not been found to cause headaches or induce tolerance in randomized controlled trials in HFpEF patients.
Modulation of the inorganic nitrate-nitrite-NO pathway represents a novel avenue by which to improve exercise capacity in HFpEF. 8 The plasma concentration of stable NO metabolites represents an attractive biomarker of NO bioavailability. NO 3 and NO 2 are the most abundant circulating NO metabolites and are generated as byproducts of NO synthase in the vascular endothelium, as well as from the ingestion of dietary inorganic NO 3 and NO 2 . 8 In a matched cohort, HFpEF participants were found to have reduced NO metabolites compared with HFrEF, suggesting either compromised endothelial function or poor dietary intake. 9 Dietary NO 3 can stimulate the nitrate-nitrite-NO pathway and partly compensate for disturbances in endogenous NO generation from NO synthase.
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The production of NO through the nitrate-nitrite-NO pathway has been shown to favourably impact late systolic load.
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Pulsatile arterial load has long been known to have an important impact on LV function and remodelling. In particular, wave reflections originating at sites of impedance mismatch (i.e. bifurcations, points of change in arterial size or wall stiffness, predominantly in middle-sized conduit arteries) in the periphery are conducted back to the heart during ejection, and have been shown to increase late systolic pulsatile load and have adverse long-term consequences on LV relaxation, hypertrophy and fibrosis. Selective vasodilators, such as inorganic NO 3 , that enhance the nitrate-nitrite-NO pathway can counter peripheral arterial effects with a potential for chronic disease-modifying benefits in HFpEF. 8 With the failure of organic NO 3 in the NEAT-HFpEF trial, the door has been opened for inorganic NO 3 to re-emerge in clinical trials. Zamani et al. 11 performed a non-invasive double-blind, crossover study in 17 subjects, demonstrating a single dose of NO 3 -rich beetroot juice (NO 3 , 12.9 mmol) could improve exercise capacity in patients with HFpEF by targeting abnormal peripheral responses to exercise, improving oxygen delivery to exercising muscles, and reducing late systolic aortic pressure augmentation, suggesting a favourable impact on LV pulsatile load. Using invasive haemodynamic assessments in 28 patients with HFpEF, Borlaug et al. 12 showed greater increases in cardiac output, improved systemic vasodilatation, and increased LV systolic performance after acute sodium nitrite (NaNO 2 ) infusions. In a subsequent study, Eggebeen et al. 13 showed that one week of daily dosing with low dose beetroot juice (NO 3 , 6.1 mmol) also significantly improved submaximal aerobic endurance and resting blood pressure in 20 patients with HFpEF. In contrast to the unfavourable effects of organic NO 3 in HFpEF, these trials have demonstrated that inorganic NO 3 and NO 2 can improve exercise capacity in patients with HFpEF.
Cerebral and systemic vasodilatory effects: is there a difference between organic vs. inorganic nitrates?
Given the differing mechanisms of action and side effect profiles of organic vs. inorganic nitrates, it is intriguing to think that these two classes of drugs have differential effects on the carotid and systemic arterial circulations, which could have major implications in the treatment of HFpEF. In this issue of the Journal, Chirinos et al.
14 report the results of detailed sub-studies that examined aortic and carotid pressure-flow relations to differentiate the impact of inorganic and organic nitrates on pulsatile flow dynamics in patients with HFpEF. In the first sub-study, the authors measured carotid and aortic pressure-flow relations before and after the administration of 0.4 mg of sublingual NTG (n = 26), and in a separate sub-study, in response to 12.9 mmol of potassium nitrate (KNO 3 ; n = 16). Several indices, including aortic impedance; reflection coefficients quantifying the net effect of arterial wave reflections; the Buckberg index, an assessment of the effect of pulsatile haemodynamics on myocardial oxygen demand (systolic load) vs. supply (perfusion pressure); and carotid dilatation, resistance, and impedance were measured in both studies.
While NTG substantially reduced systolic blood pressure, it did not consistently reduce arterial wave reflections across the first three harmonics of the pressure-flow relation (in which most of the pulsatile energy is contained) and it produced profound vasodilatation in the carotid territory. In contrast, inorganic NO 3 produced consistent reductions in wave reflections across the first three harmonics, with a delay in the reflected aortic wave well into diastole, without significant systemic hypotension or cerebrovascular dilatation. These haemodynamic differences likely contribute to the differential clinical effects of organic vs. inorganic nitrates observed in recent trials. By selectively avoiding cerebral vasodilatation, reducing pulsatile load without lowering central blood pressure, and delaying the reflected aortic wave into diastole, inorganic nitrates appear to have a clear advantage over organic nitrates: they do not cause headaches, they do not cause systemic hypotension (and its attendant ill effects in HFpEF), and they increase coronary perfusion pressure by shifting the reflected aortic wave from systole towards diastole.
Although the study by Chirinos et al. used comprehensive, state-of-the-art non-invasive pressure-flow analyses of the aortic and carotid circulations, there are several limitations that must be considered, as noted by the authors. The most important limitations include the relatively small sample sizes, the lack of a head-to-head comparison of organic vs. inorganic nitrates, and the acute, one-time dosing involved in the studies (thereby limiting generalization to the chronic effects of these therapies in HFpEF 
Future directions and conclusions
There are two randomized controlled trials underway evaluating the therapeutic effects of inorganic NO 3 and NO 2 in HFpEF. The KNO 3 CK OUT-HFpEF trial (ClinicalTrials.gov identifier NCT02840799) is a double-blind, placebo-controlled crossover trial to evaluate whether oral KNO 3 improves exercise capacity and oxygen uptake in patients with HFpEF after 6 weeks of therapy. The INDIE-HFpEF trial (ClinicalTrials.gov identifier NCT02742129) is a double-blind, placebo-controlled crossover trial to evaluate the effect of inhaled NaNO 2 on exercise capacity (peak oxygen consumption) after 4 weeks of therapy. Secondary outcomes in both studies will evaluate the impact of inorganic nitrates on diastolic function and patient-reported quality of life scores.
As we eagerly await the results of these clinical trials, it is important to remember that the differences between inorganic and organic nitrates are not 'all in your head'. Chirinos and colleagues have conducted important studies that demonstrate significantly different effects of inorganic vs. organic nitrates on the cerebral and systemic arterial vascular beds, providing proof that the major disparities in the frequency of debilitating headaches and activity intolerance experienced by HFpEF patients who take organic vs. inorganic nitrates trials are real.
